Research Tracker›Biomarker Atlas›Marker Pages›Anti-Bb IgG (synovial PCR)

Anti-Bb IgG (synovial PCR): biomarker evidence

Anti-Bb IgG (synovial PCR) appears in 1 entry of the OSMF biomarker atlas, covering Lyme Disease. Across those entries it is mixed in 1. It is currently reported in a single condition in this atlas; cross-condition comparison will be added as the dataset grows. Each row below links to a page with the comparison group, associated symptoms, test details and primary citation.

Lyme Disease

Where Anti-Bb IgG (synovial PCR) is reported

Also listed as: Lyme arthritis molecular

ConditionDirectionCompared againstAssociated symptomsSource
Lyme Disease↕ inconsistentNon-Lyme joint fluidPersistent Lyme arthritisLantos et al. 2021

Frequently asked questions

In which conditions is Anti-Bb IgG (synovial PCR) altered?

In the OSMF atlas Anti-Bb IgG (synovial PCR) is reported in Lyme Disease. It is mixed in 1 across 1 entries.

Is there a standard clinical test for Anti-Bb IgG (synovial PCR)?

The atlas entries for Anti-Bb IgG (synovial PCR) do not carry a LOINC code, which usually means the marker was measured with research assays or study-specific methods rather than a routine clinical panel.

Is one abnormal Anti-Bb IgG (synovial PCR) result diagnostic?

No single biomarker result is diagnostic of any of these conditions. Findings reflect group averages from published cohorts with substantial overlap between patients and controls.

Cite this page

Open Source Medicine Foundation. (2026). Anti-Bb IgG (synovial PCR) across conditions: biomarker evidence. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/markers/anti-bb-igg-synovial-pcr.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-06-29 · Browse: Biomarker Index · All marker pages · Biomarker Atlas

Disclaimer: Educational synthesis of peer-reviewed research; not medical advice. Findings are group-level and vary with study design. Discuss any result with a qualified clinician.